Evidence map›Paper›PMID 32993812›Full record

ArticleMolecular neurodegeneration2020

Integrated analysis of the aging brain transcriptome and proteome in tauopathy.

Carl Grant Mangleburg, Timothy Wu, Hari K Yalamanchili, Caiwei Guo, Yi-Chen Hsieh, Duc M Duong, Eric B Dammer, Philip L De Jager, Nicholas T Seyfried, Zhandong Liu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 90 citations in OpenAlex.

  1. Article
  2. APOE4 disrupts the central dogma by arresting neuronal proteome dynamics.bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Exploring the PLD1-tau interaction in Frontotemporal Dementia.bioRxiv : the preprint server for biology · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Carl Grant MangleburgDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
Timothy WuDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
Hari K YalamanchiliDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
Caiwei GuoDepartment of Neuroscience, Baylor College of Medicine, Houston, TX, 77030, USA.
Yi-Chen HsiehDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
Duc M DuongDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Eric B DammerDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Philip L De JagerCenter for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for the study of Alzheimer's disease and the aging brain, Columbia University Medical Center, New York, NY, 10032, USA.
Nicholas T SeyfriedDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Zhandong LiuDepartment of Pediatrics, Baylor College of Medicine, Houston, TX, 77030, USA.
Joshua M ShulmanDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA. Joshua.Shulman@bcm.edu.ORCID 0000-0002-1835-1971
Baylor College of Medicine · USEmory University · USBroad Institute · US

Funding

Supplement to AMP-AD Brain Proteomic Network Enhancement, Validation and Translation into CSF BiomarkersU01AG061357 · NIA · EMORY UNIVERSITY · PI LEVEY, ALLAN I, SEYFRIED, NICHOLAS THOMAS · 2018 to 2022
$9.1M
Discovery of Novel Proteomic Targets in Alzheimer's DiseaseU01AG046161 · NIA · EMORY UNIVERSITY · PI BENNETT, DAVID ALAN, GESCHWIND, DANIEL H · 2014 to 2018
$8.4M
Identifying therapeutic targets that confer synaptic resilience to Alzheimer's diseaseR01AG061800 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Christopher A. Gaiteri, Jeremy H. Herskowitz · 2018 to 2026
$6.9M
Functional Dissection of Alzheimer's Disease Networks in Drosophila: from Association to Causal Modulators of Age-Dependent NeurodegerationR01AG057339 · NIA · BAYLOR COLLEGE OF MEDICINE · PI BOTAS, JUAN, LIU, ZHANDONG · 2017 to 2021
$3.8M
Identifying the molecular systems, networks, and key molecules that underlie cognitive resilienceR01AG057911 · NIA · UPSTATE MEDICAL UNIVERSITY · PI GAITERI, CHRISTOPHER A. · 2017 to 2021
$3.8M
Tau-Spliceosome Interactions in Alzheimer's DiseaseR01AG053960 · NIA · BAYLOR COLLEGE OF MEDICINE · PI SEYFRIED, NICHOLAS THOMAS, SHULMAN, JOSHUA M · 2016 to 2020
$3.2M
Brain - Plasma Proteomics Biomarker Discovery and Validation in the US and UKRF1AG057471 · NIA · EMORY UNIVERSITY · PI BENNETT, DAVID ALAN, LEVEY, ALLAN I · 2017 to 2017
$3.2M
Building a high-resolution multi-omic AD interactome with the AMP-AD and M2OVE-AD ProjectsRF1AG057470 · NIA · EMORY UNIVERSITY · PI HAJJAR, IHAB M, SEYFRIED, NICHOLAS THOMAS · 2017 to 2017
$3.1M
Functional Validation of the CD2AP Susceptibility Network in Alzheimer's DiseaseR01AG050631 · NIA · BAYLOR COLLEGE OF MEDICINE · PI SHULMAN, JOSHUA M · 2016 to 2020
$2.5M
Dissecting causal events in Alzheimer's diseaseF31AG067677 · NIA · BAYLOR COLLEGE OF MEDICINE · PI MANGLEBURG, CARL GRANT · 2020 to 2021
$84k
NIA NIH HHS F31 AG067677NIA NIH HHS R01 AG050631NIA NIH HHS R01 AG053960NIA NIH HHS R01 AG057339NIA NIH HHS R01 AG057911NIA NIH HHS R01 AG061800NIA NIH HHS RF1 AG057470NIA NIH HHS RF1 AG057471NIA NIH HHS U01 AG046161NIA NIH HHS U01 AG061357
6 · The paper itself

Abstract

backgroundTau neurofibrillary tangle pathology characterizes Alzheimer's disease and other neurodegenerative tauopathies. Brain gene expression profiles can reveal mechanisms; however, few studies have systematically examined both the transcriptome and proteome or differentiated Tau- versus age-dependent changes.

methodsPaired, longitudinal RNA-sequencing and mass-spectrometry were performed in a Drosophila model of tauopathy, based on pan-neuronal expression of human wildtype Tau (Tau

resultsTau

conclusionsOur results comprise a powerful, cross-species functional genomics resource for tauopathy, revealing Tau-mediated disruption of gene expression, including dynamic, age-dependent interactions between the brain transcriptome and proteome.

Indexed as

AgingAnimalsBrainDrosophilaHumansMutationTauopathiestau ProteinsTranscriptomeMAPT protein, humantau ProteinsAlzheimer’s diseaseInflammationInnate immunityMAPTProteomeTauTranscriptome

Identifiers

PMID32993812
PMCPMC7526226
OpenAlexW3090585201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.